[A16-12] Empagliflozin - Benefit assessment according to §35a Social Code Book V

Last updated 01.06.2016

Project no.:

Commission awarded on 29.02.2016 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Empagliflozin in type 2 diabetes: added benefit for single agent and fixed combination again not proven

Information on patient-relevant outcomes missing / new data unsuitable for assessment of the added benefit in Germany

Current document

Federal Joint Committee (G-BA)

2016-09-01 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.